Objectives: For locally advanced prostate cancer management, medical androgen deprivation and surgical castration are alternatives. These hormonal treatments may cause a myriad of side effects, such as osteoporosis with increased risk of fractures, anemia, behavioral changes and lack of sexual interest. We evaluated the feasibility of intermittent androgen replacement in surgically castrated patients with significant side effects. Methods: Five patients with advanced prostate cancer, ranging from 71 to 77 years of age (mean age ¼ 74 years), surgically castrated for at least 3 years, with important symptoms of hypoandrogenism received testosterone replacement. They were followed with PSA and testosterone measurement every other month and bone scans every 6 months. Results: For the first year all patients improved significantly, none of them showed PSA increase over 10 ng/ml. There was no evidence of local recurrence or distant disease. After 18 months, only one patient (20%) had a significant PSA increase, controlled by androgen withdrawal. No side effects or metastasis were observed. Conclusions: Hormonal replacement in patients that underwent castration seems to be feasible in improving intense symptoms associated to androgen deprivation. After 18 months, no evidence of recurrence was noted. It is an experimental alternative for highly symptomatic patients, but the short follow-up and the small number of patients cannot allow for definitive conclusions and should be studied further.
Introduction
Androgen deprivation is effective in the treatment of locally advanced prostate cancer (CaP). 1 Actually, it is expected that about 85% of CaP patients respond to androgen deprivation. 2 The current forms of androgen blockage are bilateral orchidectomy, antiandrogenics, LHRH agonists/antagonists and estrogen-based medications. 3 Hypogonadism, either after orchidectomy or medication, is associated to sexual dysfunction, loss of libido, osteoporosis, increased risk of fractures, anemia and decline in muscular strength and intellectual vitality. [4] [5] [6] [7] A more recent alternative is intermittent androgen suppression, which would avoid deleterious side effects of hormonal withdrawal and also lowering costs of continuous treatment. Besides, it would theoretically retard the growth of hormone-independent cancer cells. 8 Replacement was described in hypogonadal men after radical prostatectomy for organ-confined cancer. 9 For patients whose biochemical response was satisfactory after surgical castration and that developed intense systemic symptoms of androgen deprivation, we introduced an alternative to intermittent blockage, using intermittent androgen replacement.
Materials and methods
Five patients with locally advanced CaP treated with subcapsular orchiectomy at least 3 years before were enrolled. Their median age was 74 years (ranging from 71 to 77 years) and all presented with significant complaints of androgen deprivation and important decrease in well being.
Patient selection included stable baseline serum PSA (10 ng/ml arbitrarily selected as the acceptable upper limit) and testosterone at castration level (Table 1) .
Pretreatment bone scans were negative for metastasis. The study was reviewed by a research board and informed consent was signed prior to enrollment. Androgen reposition was performed with 250 mg of Testosterone Enanthate intramuscularly every 3 weeks, with every other month evaluation of signs and symptoms, digital rectal examination, serum PSA, testosterone dosage and liver enzymes. Bone scans were performed at 6 months intervals. Quality of Life was evaluated by subjective questions and improvement of complaints. No validated QoL questionnaire was used.
Results
All five patients reported important subjective symptom improvement, mainly fatigue, mood alteration and wellbeing sensation after hormonal replacement.
After 1 year treatment, no patient presented increase in serum PSA over 10 ng/dl nor evidence of bone metastasis. After 18 months follow-up, four patients (80%) still had PSA below 10 ng/dl, without evidence of metastasis. Only one patient presented a PSA of 12 ng/ml after 14 months, when replacement was resumed. The PSA decreased to 7.2 ng/ml (Table 2 ) and the patient had stable serial PSA measures and no evidence of recurrence or distant disease.
None of the patients developed bone metastasis or recurrence of local disease after a median follow-up of 24 months (range, 18-30 months). No patient presented side effects or laboratorial abnormalities due to androgen replacement during the study and all patients were satisfied with their quality of life during replacement therapy.
Discussion
The symptoms associated with androgen deprivation are sometimes so intense, leading to an important decline in quality of life. These patients usually complain of the severity of the symptoms, requiring some kind of treatment for relief. It is important to consider that they will have to bare those symptoms for a long period, since the average interval between castration and progression ranges from 18 to 30 months. 3 One recent study demonstrated that testosterone replacement was performed in 10 patients with hypogonadism that underwent previous radical prostatectomy for organ-confined cancer, with significant improvement in their quality of life assessments. 9 In our study, all five patients reported amelioration of their complaints without evidence of disease recurrence. Their serum PSA level were below 10 ng/dl, although only one patient (20%) had biochemical evidence of progression on the 14th month, returning to expected PSA values after replacement was resumed.
Although we did not use a validated questionnaire to evaluate quality of life before and after reposition, the reported improvement in symptoms and well being in all patients was evident. The intermittent blockage is very attractive, with significant lowering of side effects and costs, as reported by some authors. 8, 10 It is important to state that not all patients are compliant or able to afford those expensive medications. That is the reason surgical castration is still employed, especially in older patients or those who live far away from specialized centers. Androgen replacement in castrated patients with severe side effects did not demonstrate faster clinical or bichemical disease recurrence and seems to be a possible treatment option, although yet experimental. Significant subjective improvement in complaints was reported by all patients in this pilot study and no evidence of local recurrence or distant disease was encountered after a mean follow-up of 18 months. Although follow-up is short, androgen replacement is an experimental treatment and should only be used in selected very symptomatic patients under careful supervision until definitive conclusions are achieved.
Conclusion
Hormonal replacement in patients that underwent castration seems to be feasible in improving intense symptoms associated to androgen deprivation. After 18 months, no evidence of recurrence was noted. It is an experimental alternative for highly symptomatic patients, but the short follow-up and the small number of patients cannot allow for definitive conclusions and should be studied further. Intermittent androgen replacement U Ferreira et al
